A Study of MORAb-202 in Participants With Previously Treated Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC)
NCT ID: NCT05577715
Last Updated: 2025-09-04
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE2
31 participants
INTERVENTIONAL
2022-11-14
2024-08-12
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study Of Combined C- MET Inhibitor And PAN-HER Inhibitor (PF-02341066 And PF-00299804) In Patients With Non- Small Cell Lung Cancer
NCT01121575
Nimotuzumab Plus Docetaxel in Chemotherapy-Refractory/Resistant Patients With Advanced Non-Small-Cell Lung Cancer
NCT00983047
First-line Treatment With Dacomitinib Plus Anlotinib for Patients With Advanced NSCLC With EGFR 21L858R Mutations
NCT05271916
A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLC
NCT04606771
Phase 2 Study of Dacomitinib in NSCLC
NCT04027647
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
MORAb-202
MORAb-202
Specified dose on specified days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MORAb-202
Specified dose on specified days
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Measurable target disease assessed by the investigator according to RECIST 1.1.
* Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1
Exclusion Criteria
* Significant third-space fluid retention (eg, ascites or pleural effusion) that requires repeated drainage.
* Prior pneumonectomy. Prior lobectomy and segmentectomy are allowed \> 12 months before treatment.
* Recent chest radiotherapy. Participants with chest or chest wall radiation may be permitted if chest radiation is documented \> 6 months before starting study treatment.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Eisai Inc.
INDUSTRY
Bristol-Myers Squibb
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bristol-Myers Squibb
Role: STUDY_DIRECTOR
Bristol-Myers Squibb
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Local Institution - 0007
Orange, California, United States
Local Institution - 0035
Lone Tree, Colorado, United States
Local Institution - 0043
Clermont, Florida, United States
Local Institution - 0010
Orange City, Florida, United States
Local Institution - 0001
Marietta, Georgia, United States
Local Institution - 0005
Louisville, Kentucky, United States
Local Institution - 0044
Silver Spring, Maryland, United States
Henry Ford Hospital
Detroit, Michigan, United States
Local Institution - 0002
Kansas City, Missouri, United States
Local Institution - 0011
Charlotte, North Carolina, United States
Local Institution - 0034
Arlington, Texas, United States
Local Institution - 0045
Flower Mound, Texas, United States
Local Institution - 0033
Fairfax, Virginia, United States
Local Institution - 0040
Wollongong, NS, Australia
Local Institution - 0012
Ballarat Central, Victoria, Australia
Local Institution - 0022
Murdoch, Western Australia, Australia
Local Institution - 0039
Mons, WHT, Belgium
Local Institution - 0036
Roeselare, , Belgium
Local Institution - 0028
Providencia, SA, Chile
Local Institution - 0030
Independencia, , Chile
Local Institution - 0027
Recoleta, , Chile
Local Institution - 0023
Santiago, , Chile
Local Institution - 0017
Rouen, , France
Local Institution - 0015
Suresnes, , France
Local Institution - 0014
Toulon, , France
Local Institution - 0038
Villejuif, , France
Local Institution - 0020
Málaga, MA, Spain
Local Institution - 0019
Majadahonda (Madrid), M, Spain
Local Institution - 0025
Barcelona, , Spain
Local Institution - 0021
Barcelona, , Spain
Local Institution - 0018
Madrid, , Spain
Local Institution - 0026
Santiago de Compostela, , Spain
Local Institution - 0031
Seville, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Related Links
Access external resources that provide additional context or updates about the study.
BMS Clinical Trial Information
BMS Clinical Trial Patient Recruiting
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2022-000131-23
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
MORAb-202-G000-203
Identifier Type: OTHER
Identifier Source: secondary_id
CA116-003
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.